Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Collegium Pharma
(NQ:
COLL
)
35.96
+0.34 (+0.95%)
Streaming Delayed Price
Updated: 10:36 AM EDT, Aug 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Collegium Pharma
< Previous
1
2
3
4
Next >
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
August 20, 2024
On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier.
Via
Investor's Business Daily
The Analyst Verdict: Collegium Pharmaceutical In The Eyes Of 4 Experts
August 09, 2024
Via
Benzinga
COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
COLL stock results show that Collegium Pharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Collegium Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
In a market where value is scarce, NASDAQ:COLL offers a refreshing opportunity with its solid fundamentals.
August 06, 2024
COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) is probably undervalued for the fundamentals it is displaying.
Via
Chartmill
Demystifying Collegium Pharmaceutical: Insights From 4 Analyst Reviews
May 10, 2024
Via
Benzinga
Critical Insights From Collegium Pharmaceutical Analyst Ratings: What You Need To Know
April 11, 2024
Via
Benzinga
Where Collegium Pharmaceutical Stands With Analysts
February 23, 2024
Via
Benzinga
Recap: Collegium Pharmaceutical Q4 Earnings
February 22, 2024
Via
Benzinga
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
July 29, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024
July 25, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
NASDAQ:COLL is an undervalued gem with solid fundamentals.
July 16, 2024
COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) is probably undervalued for the fundamentals it is displaying.
Via
Chartmill
Dr. Reddy's Labs Stock Sees Improved Technical Strength
June 28, 2024
On Friday, Dr. Reddy's Labs ADR stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 76.
Via
Investor's Business Daily
Analyst Expectations For Collegium Pharmaceutical's Future
February 02, 2024
Via
Benzinga
Why Collegium Pharmaceutical Shares Are Gaining Today
January 03, 2024
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced FY24 financial
Via
Benzinga
7 Biotech Stocks to Buy on the Dip: June 2024
June 24, 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.
Via
InvestorPlace
NASDAQ:COLL appears to be flying under the radar despite its strong fundamentals.
June 24, 2024
COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) is an undervalued gem with solid fundamentals.
Via
Chartmill
Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
June 13, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Participate in Jefferies Global Healthcare Conference
May 29, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Announces $35 Million Accelerated Share Repurchase Program
May 13, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Misses Revenue for Q1 2024
May 09, 2024
COLL stock results show that Collegium Pharmaceutical beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Collegium Reports First Quarter 2024 Financial Results
May 09, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Announces CEO Transition
May 09, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
April 29, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
April 25, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
April 11, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
February 22, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
February 08, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday
January 03, 2024
U.S. stocks traded lower, with the Nasdaq Composite falling around 150 points on Wednesday. Shares of TDCX Inc. (NYSE: TDCX) rose sharply during Wednesday’s session after it disclosed receiving a...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.